Natera's Signatera Genome Could Emerge as Dominant Clinical Offering Within Few Years, RBC Says

MT Newswires Live09-25 23:30

Natera's (NTRA) Signatera Genome, the new ultra sensitive version of its molecular residual disease test, could emerge as the dominant clinical offering within a few years, RBC Capital Markets said in a note.

The company plans to run ultra Signatera Genome alongside Signatera Classic in prospective trials slated for readout in 2027, which will yield a prospective data advantage that the company believes competitors will struggle to replicate, RBC said on Thursday.

RBC further said that pharma is a meaningful additional growth leg, noting that the publication of IMvigor data last Fall saw pharma engagement that materially exceeded Natera's own expectations, thus, driving interest in using Signatera in clinical trials.

Additionally, another opportunity lies in monetizing Natera's longitudinal Signatera datasets, with artificial intelligence unlocking actionable insights from this data, RBC said.

RBC raised its price target on the company's stock to $460 from $350 and maintained its outperform rating.

Price: 413.20, Change: +4.40, Percent Change: +1.08

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2670628425?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-25 23:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2670628425","market":"hk","top_or_hot":-1,"title":"Natera's Signatera Genome Could Emerge as Dominant Clinical Offering Within Few Years, RBC Says","media":"MT Newswires Live","content":"<html><body><p> Natera's (NTRA) Signatera Genome, the new ultra sensitive version of its molecular residual disease test, could emerge as the dominant clinical offering within a few years, RBC Capital Markets said in a note.</p><p>The company plans to run ultra Signatera Genome alongside Signatera Classic in prospective trials slated for readout in 2027, which will yield a prospective data advantage that the company believes competitors will struggle to replicate, RBC said on Thursday.</p><p>RBC further said that pharma is a meaningful additional growth leg, noting that the publication of IMvigor data last Fall saw pharma engagement that materially exceeded Natera's own expectations, thus, driving interest in using Signatera in clinical trials.</p><p>Additionally, another opportunity lies in monetizing Natera's longitudinal Signatera datasets, with artificial intelligence unlocking actionable insights from this data, RBC said.</p><p>RBC raised its price target on the company's stock to $460 from $350 and maintained its outperform rating.</p><p>Price: 413.20, Change: +4.40, Percent Change: +1.08</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Natera's Signatera Genome Could Emerge as Dominant Clinical Offering Within Few Years, RBC Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNatera's Signatera Genome Could Emerge as Dominant Clinical Offering Within Few Years, RBC Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-09-25 23:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Natera's (NTRA) Signatera Genome, the new ultra sensitive version of its molecular residual disease test, could emerge as the dominant clinical offering within a few years, RBC Capital Markets said in a note.</p><p>The company plans to run ultra Signatera Genome alongside Signatera Classic in prospective trials slated for readout in 2027, which will yield a prospective data advantage that the company believes competitors will struggle to replicate, RBC said on Thursday.</p><p>RBC further said that pharma is a meaningful additional growth leg, noting that the publication of IMvigor data last Fall saw pharma engagement that materially exceeded Natera's own expectations, thus, driving interest in using Signatera in clinical trials.</p><p>Additionally, another opportunity lies in monetizing Natera's longitudinal Signatera datasets, with artificial intelligence unlocking actionable insights from this data, RBC said.</p><p>RBC raised its price target on the company's stock to $460 from $350 and maintained its outperform rating.</p><p>Price: 413.20, Change: +4.40, Percent Change: +1.08</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NTRA","symbol_name":"Natera, Inc.","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2670628425","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2670628425","pubTimestamp":1790350202,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Natera's (NTRA) Signatera Genome, the new ultra sensitive version of its molecular residual disease test, could emerge as the dominant clinical offering within a few years, RBC Capital Markets said in","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NTRA":"Natera, Inc.","LU2065169927.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) ACC","LU0012050646.USD":"SCHRODER ISF US SMALLER COMPANIES IMPACT \"A\" (USD) INC AV","LU2065731478.USD":"ALLSPRING (LUX) WORLDWIDE FUND - SMALL CAP INNOVA \"I\" (USD) ACC","HELX":"Franklin Genomic Advancements ETF","LU1064131342.USD":"Fullerton Lux Funds - Global Absolute Alpha A Acc USD","LU0106261612.USD":"SCHRODER ISF US SMALLER COMPANIES IMPACT \"A\" ACC","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","LU0345770993.USD":"NINETY ONE GSF GLOBAL STRATEGIC EQUITY \"A\" (USD) INC","LU0345770308.USD":"NINETY ONE GSF GLOBAL STRATEGIC EQUITY \"A\" (USD) ACC","LU1988902786.USD":"FULLERTON LUX FUNDS GLOBAL ABSOLUTE ALPHA \"I\" (USD) ACC","LU0963586101.USD":"ALLIANZ GLOBAL SMALL CAP EQUITY \"AT\" ACC","LU2065170008.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) INC","LU2065171311.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) ACC","LU2065171402.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) INC","GNOM":"Global X Genomics & Biotechnology ETF","BK4139":"生物科技","LU2264538146.SGD":"Fullerton Lux Funds - Global Absolute Alpha A Acc SGD","LU0053671581.USD":"摩根大通美国小盘成长股 A(dist)"},"translate_title":"加拿大皇家银行表示，Natera 的 Signatera 基因组可能会在几年内成为主导临床产品","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GNOM":0.6,"NTRA":1.5,"HELX":0.6},"content_text":"Natera's (NTRA) Signatera Genome, the new ultra sensitive version of its molecular residual disease test, could emerge as the dominant clinical offering within a few years, RBC Capital Markets said in a note.The company plans to run ultra Signatera Genome alongside Signatera Classic in prospective trials slated for readout in 2027, which will yield a prospective data advantage that the company believes competitors will struggle to replicate, RBC said on Thursday.RBC further said that pharma is a meaningful additional growth leg, noting that the publication of IMvigor data last Fall saw pharma engagement that materially exceeded Natera's own expectations, thus, driving interest in using Signatera in clinical trials.Additionally, another opportunity lies in monetizing Natera's longitudinal Signatera datasets, with artificial intelligence unlocking actionable insights from this data, RBC said.RBC raised its price target on the company's stock to $460 from $350 and maintained its outperform rating.Price: 413.20, Change: +4.40, Percent Change: +1.08","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"merge","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2670628425","isCrawlerRequest":true}